Geneva, January 8, 2020 - Waypoint Capital, the business enterprise for investments associated with the Bertarelli Family, today announced the appointment of Elias Zerhouni, M.D., a world-renowned physician-scientist, to its Board of Directors, effective immediately.

Dr. Zerhouni is Professor Emeritus of Radiology and Biomedical Engineering at the Johns Hopkins University, and was most recently the President, Global Research and Development for Sanofi from January 2011 to July 2018. Dr. Zerhouni’s academic career was spent at the Johns Hopkins University and Hospital where he was Professor and Chair of Radiology and Biomedical Engineering and Executive Vice Dean from 1996 to 2002. He was appointed to serve as Director of the United States National Institute of Health from 2002 to 2008. From 2009 to 2010, Dr. Zerhouni was named Presidential Envoy for Science and Technology by the U.S. President and was a Senior Fellow of the Bill and Melinda Gates Foundation. He is a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering. Among his many awards is the Medal of the Légion d'honneur of the French National Order. Dr. Zerhouni serves on a number of non-profit boards, including the Lasker Foundation, the Foundation for NIH and Research America. He is also currently a director of Danaher Corporation, a Fortune 500 science and technology innovator based in Washington, D.C. He has authored over 200 publications, holds eight patents and has founded five start-up companies.

Commenting on the appointment, Ernesto Bertarelli, Chairman of Waypoint Capital, said, “We are very pleased to welcome Dr. Zerhouni to our Board of Directors and are looking forward to benefitting from his immense experience and knowledge, which reaches from academia to government to industry. He is a world-renowned expert in science and medical technology and shares our commitment to investing in biotechnology and life sciences to help improve health outcomes.”

Dr. Zerhouni said, “I am excited to be supporting Waypoint in its effort to help drive innovation and advancement in science and medicine.  I look forward to working alongside the rest of the Board and management team to share my perspectives and support Waypoint’s execution of its business growth and development.”